Opiant Pharmaceuticals focuses on developing innovative treatments for opioid use disorder and related behavioral health issues. Their product portfolio includes SUBLOCADE® (buprenorphine extended-release injection), PERSERIS® (risperidone for extended-release injectable suspension), and SUBOXONE® (buprenorphine and naloxone sublingual film), which are designed to assist patients in managing opioid dependence. These medications are available in various forms and strengths across more than 30 countries, with specific product availability and prescribing information tailored to each region. The company emphasizes the importance of patient education and safety, providing comprehensive prescribing information and patient medication guides to ensure proper use of their products.

In addition to their pharmaceutical offerings, Opiant Pharmaceuticals is committed to supporting charitable initiatives and collaborations that address opioid use disorder and overdose events. They consider requests for funding from organizations that demonstrate effective management practices and aim to positively impact the communities they serve. Their corporate contributions focus on enhancing access to care, supporting educational programs, and fostering partnerships with medical and patient advocacy organizations. This holistic approach underscores Opiant's dedication to not only providing effective treatments but also contributing to broader efforts in addiction recovery and community health.

United States

Opiant Pharmaceuticals, Inc. is now part of Indivior, and we look forward to continuing our mission to create best-in-class medicines for the treatment of addictions and drug overdose. The Opiant Pharmaceuticals page will no longer be active or monitored. Please follow Indivior for new content.

Opiant Pharmaceuticals

Company Details